Previous 10 | Next 10 |
Nevro (NYSE: NVRO ): Q1 GAAP EPS of -$1.45 misses by $0.77 . Revenue of $82.1M (-6.3% Y/Y) misses by $5.37M . Shares -10.8% . Press Release More news on: Nevro Corp., Earnings news and commentary, Healthcare stocks news,
REDWOOD CITY, Calif. , May 9, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported financial results for the first quarter ended March 31, 2019 . Rev...
REDWOOD CITY, Calif. , April 30, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the Company will be participating in the Bank of America Merr...
REDWOOD CITY, Calif. , April 23, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the Company will release its financial results for the first quart...
March 21, 2019 Palm Beach, FL – March 21, 2019 – A recent article in a medical device industry periodical, INN, said that: “2018 has been an important year for the medical device industry as M&A, technology and regulatory catalysts have impacted the market...
Gainers: Estre Ambiental (NASDAQ: ESTR ) +81% . Motif Bio plc (NASDAQ: MTFB ) +71% . Nevro (NYSE: NVRO ) +33% . Electrameccanica Vehicles (NASDAQ: SOLO ) +32% . Dragon Victory International (NASDAQ: LYL ) +21% . Fibrocell Science (NASDAQ: FCSC ) +18% . Amira Nature Foods (NYSE:...
Motif Bio plc (NASDAQ: MTFB ) +55% on iclaprim meeting with FDA. More news on: Motif Bio plc, China Bat Group, Inc., Nevro Corp., Stocks on the move, Read more ...
KalVista Pharmaceuticals (NASDAQ: KALV ) initiated with Buy rating and $35 (24% upside) price target at Needham. More news on: KalVista Pharmaceuticals, Inc., ResMed Inc., Nevro Corp., Healthcare stocks news, Stocks on the move, , Read more ...
Alexion Pharmaceuticals (NASDAQ: ALXN ) initiated with Neutral rating and $135 (6% upside) price target at Guggenheim. More news on: Alexion Pharmaceuticals, Inc., Dermira, Exelixis, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Nevro Corp. (NVRO) Q4 2018 Earnings Conference Call February 21, 2019 4:30 PM ET Company Participants Juliet Cunningham – Vice President of Investor Relations Rami Elghandour – President and Chief Executive Officer Andrew Galligan – Chief Financial Officer ...
News, Short Squeeze, Breakout and More Instantly...
Nevro to Report Second-Quarter 2024 Financial Results and Host Earnings Conference Call on August 6, 2024 PR Newswire REDWOOD CITY, Calif. , July 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-chan...
Nevro to Present at Truist Securities MedTech Conference PR Newswire REDWOOD CITY, Calif. , June 11 , 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chr...
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 PR Newswire REDWOOD CITY, Calif. , May 24, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the trea...